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Abstract
Objective: LC-MS/MS phospho-proteomics is an essential technology to help unravel the complex molecular events that
lead to and propagate cancer. We have developed a global phospho-proteomic workflow to determine activity of signaling
pathways and drug targets in pancreatic cancer tissue for clinical application.
Methods: Peptides resulting from tryptic digestion of proteins extracted from frozen tissue of pancreatic ductal
adenocarcinoma and background pancreas (n = 12), were labelled with tandem mass tags (TMT 8-plex), separated by strong
cation exchange chromatography, then were analysed by LC-MS/MS directly or first enriched for phosphopeptides using
IMAC and TiO2, prior to analysis. In-house, commercial and freeware bioinformatic platforms were used to identify relevant
biological events from the complex dataset.
Results: Of 2,101 proteins identified, 152 demonstrated significant difference in abundance between tumor and non-tumor
tissue. They included proteins that are known to be up-regulated in pancreatic cancer (e.g. Mucin-1), but the majority were
new candidate markers such as HIPK1 & MLCK. Of the 6,543 unique phosphopeptides identified (6,284 unique
phosphorylation sites), 635 showed significant regulation, particularly those from proteins involved in cell migration (Rho
guanine nucleotide exchange factors & MRCKa) and formation of focal adhesions. Activator phosphorylation sites on FYN,
AKT1, ERK2, HDAC1 and other drug targets were found to be highly modulated ($2 fold) in different cases highlighting
their predictive power.
Conclusion: Here we provided critical information enabling us to identify the common and unique molecular events likely
contributing to cancer in each case. Such information may be used to help predict more bespoke therapy suitable for an
individual case.
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Introduction
Protein phosphorylation is a common process modulating the
activity of oncogenic and tumor suppressor proteins [1–3]. In
many cases, phosphorylation results in switch-like changes in
protein function, due to modulation of protein folding, substrate
affinity, stability, and activity of its substrates, in turn affecting
signaling pathways controlling cell proliferation, migration,
differentiation, and apoptosis, dysregulation of which contribute
to the cancer phenotype [4]. Pancreatic cancer is one of the most
aggressive malignant neoplasms with a median survival of 6
months. A significant proportion of patients are diagnosed at an
advanced stage where therapy options are very limited [5]. As is
the case for other cancers, molecular targeting therapy is
promising for treatment of advanced or recurrent pancreatic
cancer [6]. Although a variety of molecular targeting drugs have
been available in the last decade and many others are also
expected in the next few years, a breakthrough is still required for
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prediction of drug effects and drug selection. For example,
sorafenib, a multi-kinase inhibitor acting on hyperactive vascular
endothelial growth factor receptor, platelet-derived growth factor
receptor and Raf, has proven efficacy in some patients with
advanced hepatocellular carcinoma [7], but we cannot currently
predict its effect on an individual patient before starting treatment.
To overcome these difficulties, it seems crucial to establish an
analytical approach to help drug selection, where expression and
activity of multiple drug targets are comprehensively assessed on a
case-by-case basis. Phosphorylation is a key event modulating
protein activity, therefore measuring protein phosphorylation is a
useful indicator of activation status.
There are hundreds of anti-cancer drug targets and oncogenic
signaling proteins that are relevant to therapeutic selection
therefore measuring expression and activation status of all using
the current gold standard analysis, immunohistochemistry (IHC),
is not feasible. In this respect, IHC maintains a role as a validation
tool. Reverse phase protein microarrays (RPMA) have limitations
due to a limited antibody repertoire and poor specificity/cross
reactivity. In addition, genomics-based technologies do not allow
phospho-signaling measurements. Liquid chromatography - tan-
dem mass spectrometry (LC-MS/MS) based proteomic approach-
es have been developed to identify and quantify thousands of
proteins and their phosphorylation sites [8,9]. In this study we
have developed an LC-MS/MS based phospho-proteomic work-
flow (SysQuant) to overcome many of the technical and bio-
informatic difficulties involved in effectively quantifying expression
and activity of signaling proteins, many of which are drug targets,
at a global or system wide level in tumor tissue. We compared
frozen resected tissue (tumor versus non-tumor background) from
twelve cases of pancreatic head ductal adenocarcinoma and
increased throughput utilising reporter ion isotopologues of TMT,
resulting in 8-plex reagents and therefore the ability to run eight
samples simultaneously [10,11]. Molecular events likely to
contribute to cancer were identified common to all cases however
some were unique to an individual case or subgroup. There also
appeared to be a relationship between time of recurrence and the
grouping of cases following principal component analysis of the T/
NT ratios of phosphopeptides. Phosphopeptide analysis using
SysQuant may identify new therapeutic targets and also help
stratify patients into different treatment regimens based on the
activation status of signaling pathways and known drug targets.
Materials and Methods
Ethical aspects and research protocol were approved by the
BioBank Committee of the Institute of Liver Studies, King’s
College Hospital (Reference No. 08/H0704/117). All participants
provided written informed consent to use their tissue samples for
research. Twelve cases of pancreatic head ductal adenocarcinoma
were selected (Table S1 in Tables S1). Additional non-confidential
clinical information such as tumor stage, gender and recurrence
can be seen for each case in Tables S2 & S3 in Tables S1. Tumor
(T) tissue samples were taken from the pancreatic tumor masses,
while non-tumor (NT) samples were from the pancreas away from
the tumor mass. All tissue samples were frozen within 30 minutes
of surgical resection and stored [at 280uC] until analysis by
SysQuant (median time of storage [18.5 months] range [4–28
months]. T versus NT were compared using SysQuant and
experimental details are described in the Methods S1 document.
In summary, this entailed protein extraction from tissue specimens
(mg amounts used for each specimen are shown in Table S4 in
Tables S1), trypsin digestion of proteins into peptides, TMT 8-plex
labelling of peptides (tumor and non-tumor tissue from 4 cases per
TMT 8-plex) followed by mixing to form a single 8-plex sample
mixture (see Table S5, in Tables S1). Each TMT 8-plex sample
was then split into three independent aliquots, each of which was
further split into 12 fractions by strong cation exchange (SCX)
chromatography (Table S6, in Tables S1). The first set of 12 SCX
fractions were then analysed directly by LC-MS/MS using
duplicate data dependent acquisition runs followed by a third
run using time dependent rejection of all features identified in runs
1 & 2. The remaining two sets of 12 fractions were first enriched
for phosphopeptides using either immobilised metal affinity
chromatography (IMAC) or TiO2 (Table S6, in Tables S1). The
resulting 24 phosphopeptide enriched fractions were also analysed
by LC-MS/MS. In total 108 separate LC-MS/MS runs were
performed for each TMT 8-plex sample. Raw mass spectrometry
data were searched against the human UniProtKB/Swiss-Prot
database using Mascot and Sequest (via Proteome Discoverer).
Peptide spectrum matches (PSMs) were rejected if identified with
only low confidence ($5% FDR), showed #75% phospho-RS
probability score, and had missing quantification channels (e.g. not
all peaks for isobaric tags visible in spectra). Raw intensity values of
isobaric tags from PSMs passing filters were used for quantifica-
tion, but first normalised using sum-scaling (as shown in Figure S1)
to reduce potential experimental/systematic bias. Log2 ratios were
calculated from isobaric tag intensities, showing the regulation
between T over NT for each case. A phosphopeptide T/NT log2
ratio is the median T/NT log2 ratio from all PSMs unique to that
specific peptide sequence. A protein T/NT log2 ratio is the
median T/NT log2 ratio from all unique non-phosphorylated
peptides unique to that specific protein. One sided t-test (one-
sample location test) was used to calculate p-values. P-values were
plotted against log2 T/NT ratios on Volcano plots to identify
significantly regulated peptides. At the protein level, annotation
using GO-terms, KEGG-pathways and Drugbank information
were added, and proteins were also mapped to pathways using
resources such as DAVID and STRING. At the phosphorylation
site level annotation using PhosphoSitePlus were added, including
known functional and biological/pathological role of the phos-
phorylation site. Partial Least Squares Discriminant Analysis (PLS-
DA) was used to model and investigate the multivariate dataset to
identify outliers and groups from all peptide isobaric tag intensities
from each filter passing PSM, as well as log2 T/NT ratios
(phosphopeptides) from all arms of the workflow (IMAC, TiO2
and non-enriched). The SysQuant workflow, combining phospho-
proteomic sample preparation, LC-MS/MS analysis, and bioin-
formatics analysis, was used to identify important molecular events
we believe contribute to pancreatic cancer in the cases analysed
here.
Results and Discussion
All peptides identified by Sequest and Mascot in this study were
exported from Proteome Discoverer and can be viewed on the zip
Files S1, S2, and S3. File S1 contains all peptides (phosphorylated
and non-phosphorylated) identified from the specimens in TMT 8-
plex-1, File S2 contains all peptides identified from specimens in
TMT 8-plex-2, and File S3 contains all peptides identified from
specimens in TMT 8-plex-3. These Supplemental zip Files display
detailed information including Sequest Xcorr, Mascot ions scores,
DM [ppm], Percolator q-values, and other important information.
Data from these excel documents were input into in-house
bioinformatic tools to identify biologically relevant events.
In total we identified 6,543 unique phosphopeptides sequences
(6,284 unique phosphorylation sites), from 2,101 proteins (Table 1).
Figure 1 shows identified peptide (phosphorylated and non-
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phosphorylated) distribution over all three arms (Non-enriched,
TiO2, IMAC) of the SysQuant workflow for each TMT 8-plex.
Figure 1 also illustrates the number of peptides detected in total for
all three analytical repeats (after combining numbers from
different fractions) in each and all TMT 8-plex samples. When
results from each of the parallel components (TiO2, IMAC, non-
enriched) are compared the benefits of a combined enrichment
approach and multiple analytical repeats (including utilisation of
the time dependent rejection list), are apparent. The largest total
number of phospho-peptides was seen using IMAC enrichment
which accounted for 79% of all unique phosphopeptides
identified. However, the TiO2 fractions uniquely identified nearly
19% of the total which would be missed using a single phospho-
peptide enrichment strategy (Figure 1: TMT 8-plex-ALL: A). The
same is true for the three analytical runs performed on each
sample. If a single data dependent run was performed only 20,318
unique peptides are seen (Figure 1: TMT 8-plex-ALL: D). A
second data-dependent run adds 5,868 peptides whilst the use of
the time dependent rejection list in run 3 allowed a further 3257
peptides to be identified overall. Collectively (run 2&3) this
represents an additional 45% over run 1 alone and 31% of the
total number of unique peptides. Importantly the peptides
identified in the third run are generally of lower abundance. We
also illustrate (Figure S2) the number of unique phosphopeptides
and non-phosphopeptides identified in each raw file, from each
SCX fraction, in each arm of the workflow (non-enrich, TiO2, and
IMAC), from each TMT 8-plex sample (TMT 8-plex-1, 2, & 3).
Of the 6543 phosphopeptides identified, 5409 were quantifi-
able. Due to the large number of quantifiable phosphopeptides
these must be viewed on a separate excel file (File S4), rather than
as part of the main document. File S4 displays the phosphopeptide
sequences, the phosphorylated residues and the protein name and
Uniprot accession number to which the peptide belongs. File S4
also displays all quantitative and statistical information relating to
the phosphopeptides in tumor versus non-tumor from all cases,
and also gives annotation information including known functional
effects of the phosphorylation event. This information was
extracted from the PhosphositePlus database and can be observed
in columns BM-CP. File S4 also provides functional information
relating to the protein, information extracted from GO terms
(columns CQ-DC) and whether such proteins are known drug
targets (columns DD-DG) extracted from the Drug Bank database.
For additional information regarding the relative protein abun-
dance and normalised phosphopeptide levels (phosphopeptide
normalised to protein level) refer to File S5. The relative
abundance of phosphopeptides in tumor versus non-tumor tissue
will change from case to case primarily due to changes in
expression level of the phosphorylated protein or due to
modulated activity of the kinases and phosphatases inducing or
reversing phosphorylation of the protein substrate, respectively. In
File S5 we normalise the relative abundance of a phosphopeptide
to the relative abundance of the respective protein. Relative
protein abundance is calculated using only non-phosphorylated
peptides therefore there are cases where we are not able to carry
out normalisation due to the absence of non-phosphorylated
peptides to some of the proteins.
PLS-DA
The first Principal Component (PC1) shows the variability
introduced due to the three different arms of the workflow. These
three arms IMAC, TiO2 and Total Protein (i.e non-enriched), as
shown in Figure 2A and Figure S3, have separated the variables
into 3 separate clusters. The solid black circle in Figure 2A depicts
the T2 hotelling space based on 95% confidence. PC1 explains
13.6% of the total variance in the dataset. The second Principal
Component (PC2) illustrates the variability introduced by different
TMT 8-plex channels. This variability highlights primarily the
patient to patient variance, which is 10.56% of the total variance
in the dataset. The between class variation, i.e Tumor (T) vs Non-
Tumor (NT), is shown by the third principal component (PC3)
which explains 14.36% of the total variance in the dataset.
Figure 2B and Figure S4 shows the grouping of variables into two
separate clusters, i.e. T and NT. Differences across the different
arms of the workflow has also affected PC3, which is illustrated by
the grouping of TotalProtein (non-enriched) peptides in a single
cluster in Figure 2B. Only patient 12 does not show any differences
in T compared to NT according to Figure 2B. The PLS bi-plots
demonstrate that there were no outliers in this dataset, as shown
on the Hoteling T2-Range plot (Figure S3). PLS confirmed that
the experiment was successful, and that there are significant
differences between T and NT. Differences across the three
different arms of the workflow exists, but TiO2 and IMAC have a
nearly equal correlation. Together PC1, PC2 and PC3 explain
38.52% of the total variance in the dataset. The remaining
variation in the dataset can be attributed to mixed effects of
analytical and biological variability.
In addition to investigating raw isobaric tag intensities in T &
NT specimens to identify outliers and groups, PLS-DA was also
used to investigate the log2 T/NT ratios from all phospho-peptides
(median from IMAC, TiO2, Non-enriched) in each case, as shown
in Figure 2C. A subtle relationship between the grouping of cases
and the time of recurrence appears to exit, however the number of
biological repeats would need to be increased before coming to
any final conclusions. That being said it is interesting to observe
cases 14 and 9 grouped closely and both cases experienced very
early recurrence at 2 and 5 months after surgery, respectively.
Cases 10 and 8 also grouped together, but far away from all other
cases. Case 10 showed recurrence at 31 months and case 8 had no
sign of recurrence even 23 months post-surgery. Cases 4, 12, 1, 7,
5, and 13 grouped together and these showed recurrence between
10 to 21 months post-surgery. Interestingly case 6, which is yet to
show recurrence, also grouped with the cases that showed
recurrence at 10 to 21 months. Case 11 did not group with any
other cases.
Significantly regulated protein expression
We determined the relative abundance of proteins in tumor
compared to non-tumor tissue, using median log2 T/NT ratios of
the non-phosphorylated peptides unique to each protein as
surrogates to calculate the relative abundance of the respective
proteins. A one sided t-test was used to calculate p-values and these
were plotted against log2 T/NT ratios on a volcano plot to detect
significant (Log2 T/NT$0.3 or #20.3 and p#0.05) regulations
over all cases (Figure 3A). In total there were 152 proteins
significantly regulated based on Log2 T/NT$0.3 or #20.3 and
p#0.05 (File S6_Sheet ‘Pro_TvNT.or,0.3_p,0.05’). Table 2
displays the 12 most significantly upregulated proteins in tumor
compared to non-tumor tissue, and also provides a description of
any known function of each protein or association with cancer
[13–31]. Overexpression of Mucin-1 is often associated with
cancer and we also found Mucin-1 to be significantly up-regulated
in pancreatic tumor tissue. Interestingly we found more significant
up-regulated proteins than Mucin-1, some of which may prove to
be more specific markers of pancreatic cancer, perhaps even new
therapeutic targets e.g. Homeodomain-interacting protein kinase 1
(HIPK1). HIPK1, which was elevated in tumor compared to non-
tumor in all cases (median log2 T/NT = 1.00; p = 1.59 E -04), is
one of four HIPK serine/threonine kinases known to interact with
Phosphorylome in Pancreatic Cancer
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Figure 1. Number of Identified Peptides. Venn diagrams demonstrate the number of; A: unique phosphopeptide sequences, B: unique non-
phosphopeptide sequences, and C: total number of unique peptide sequences identified in the TiO2, IMAC, and/or non-enrich arm of the SysQuant
workflow, across all three TMT 8-plex samples in total (TMT 8-plex-ALL) and individually per TMT 8-plex (TMT 8-plex 1, TMT 8-plex 2, TMT 8-plex 3). D:
demonstrates the level of overlap we observe for peptide identifications from analytical run 1, analytical run 2, and analytical run 3 (including time
dependent rejection list compiled from identifications from run 1 and 2).
doi:10.1371/journal.pone.0090948.g001
Phosphorylome in Pancreatic Cancer
PLOS ONE | www.plosone.org 4 March 2014 | Volume 9 | Issue 3 | e90948
and regulate the activity of numerous cellular proteins including
several transcription factors and cofactors [32,33,34]. HIPKs have
been implicated in the control of a range of cellular pathways to
regulate various processes including the DNA damage response,
tissue specification, and proliferation [34].
To better understand the biological processes and KEGG
signaling pathways differing between tumor and non-tumor we
selected the accession numbers of all significantly modulated
proteins and uploaded these to the DAVID Bio-informatic
resource. The Focal Adhesion KEGG signaling pathway was
most significantly affected giving a Benjamini score of 1.0E-3.
Significantly modulated Focal Adhesion proteins included; Talin-
1, Filamin-A, Filamin-B, Filamin-C, Vinculin, Fibronectin,
Zyxin, and Myosin light chain kinase, smooth muscle (Figure 4
& File S6_Sheet; FA & lamellipodium). Talin-2, Focal adhesion
kinase 1 (FAK1), Protein phosphatase 1 regulatory subunit 12A
were also focal adhesion proteins and significantly modulated but
can only be seen in File S6, as these proteins were not
quantifiable in some cases and Figure 4 only shows proteins
quantifiable in all cases (e.g. no N/A). All of these focal adhesion
proteins, except FAK1, were significantly up-regulated in tumor
versus non-tumor suggesting increased size and/or frequency of
focal adhesions in cells within tumor. Focal adhesions are known
to play a role in migration of many cell types [35,36,37]. During
migration the focal adhesions can anchor cells to the extracellular
matrix following the formation of cell projections or protrusions;
such as pseudopodium, filopodium, and lamellipodium [37]. The
focal adhesion proteins Vinculin and Myosin Light Chain Kinase
are also known to be involved in formation of lamellipodia and
promote cell motility. On Figure 4 we list proteins known to be
involved in formation of growth projections and focal adhesions,
seen to be significantly modulated and measureable in all cases.
The plasma membrane spanning extracellular matrix receptors
(Integrins) are essential components of the focal adhesions
however we did not observe statistically significant modulation
of any integrin expression but did observe significant modulation
of integrin phosphorylation, as discussed later. The assembly of
focal adhesions also involves activation of Rho signaling as well as
myosin-induced contractility [37]. Figure 4 also shows Myosin 9,
10, 11, and 14 were significantly elevated in tumor compared to
non-tumor tissue.
Functional roles of four proteins in Figure 4 (LIM and SH3
domain protein 1, Moesin, Palladin, and PDZ and LIM domain
protein 7) have already been discussed in table 2, but Alpha-
actinin-4 (ACTN4) is an actin-binding protein with multiple roles
in different cell types. In non-muscle cells, it is found along
microfilament bundles and adherens-type junctions, where it is
involved in binding actin to the membrane. It is believed to be
involved in metastatic processes as Li Fu et al [38] demonstrated
that overexpression of ACTN4 in combination with 67 LR is
associated with Esophageal squamous cell carcinoma (ESCC)
progression. They demonstrated that ACTN4 was differentially
expressed in ESCC tissue compared to normal tissues and that
expression levels of ACTN4 were progressively increased from
stage I to III. Clinicopathological correlation using TMA revealed
that overexpression of ACTN4 was significantly associated with
advanced tumor stage (P = 2.6E-2) and lymph node metastasis
(P = 4.9E-02) [38]. Plectin has also been proposed as a cancer
biomarker, especially for pancreatic cancer [39]. Although
normally a cytoplasmic protein, plectin is expressed on the cell
membrane in pancreatic ductal adenocarcinoma (PDAC) and can
therefore be used to target PDAC cells [39]. Our study confirms
that both cancer biomarkers are significantly over expressed in
tumor compared to non-tumor tissue in pancreatic cancer patients
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(median log2 T/NT = 0.29 and p-value = 3.33E-02 for ACTN4,
and median log2 T/NT = 0.32 and p-value = 1.63E-03 for
Plectin).
Catenin delta-1 is necessary to the formation of cell–cell
adhesion (adherens junctions) through its interaction with the
cytoplasmic tail of classical and type II cadherins. Catenin delta-1
Figure 2. Partial Least Squares Discriminant Analysis (PLS-DA). A: PC1 and PC2 score plot of the first two principal components describing
13.6% (PC1) and 10.6% (PC2) of the total variance in the data (raw isobaric tag intensities from each PSM passing set filters). The circle depicts the T2
hotelling space based on 95% confidence. B: PC2 and PC3 score plot of the next principal components describing 10.6% (PC2) and 14.4% (PC3) of the
total variance in the data. C: PC1 and PC2 score plot of the first two principal components describing 25.8% (PC1) and 19.3% (PC2) of the total
variance in the data (median log2 T/NT ratios of all quantifiable phosphopeptides in each case). Here we also display the time of recurrence in months
for each case, following surgery.
doi:10.1371/journal.pone.0090948.g002
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also modulates the activities of the Rho family of GTPases (RhoA,
Rac, and Cdc42), suggesting that along with other Src substrates,
catenin delta-1 regulates actin dynamics. Thus, catenin delta-1 is a
master regulator of adherens junction formation, and likely
participates in regulating the balance between adhesive and motile
cellular phenotypes [40]. Here we observe significantly decreased
levels of the catenin delta-1 in tumor compared to non-tumor
tissue (median log2 T/NT =20.29 and p-value = 1.34E-02).
When considering the important role catenin delta-1 plays in
forming/maintaining adherens junctions between epithelial cells,
and considering our observed decrease in expression and
phosphorylation of this protein it suggests that these events may
contribute to dissociation of epithelial cells, hence epithelial to
mesenchymal transition in pancreatic cancer.
Of particular interest is discovering that Myosin light chain
kinase (MLCK) is significantly overexpressed in tumor compared
to non-tumor tissue (median log2 T/NT = 0.5 & p-value = 2.95E -
02). MLCK is a Ca2+/calmodulin-dependent protein kinase that
regulates a variety of cellular functions, such as, muscle
contraction and cell migration, via phosphorylation of myosin
light chain proteins. Since tumor cell migration is a key step in
tumor spread, myosin light chain kinase (MLCK) may be regarded
as a therapeutic target for preventing tumor spread. In fact,
MLCK activation and expression have been found to be positively
related with metastatic propensity. Moreover, MLCK inhibitors
have been shown to diminish the invasiveness of various cancer
cells [41]. Interestingly cases 14, 9, 4, and 13 have highest levels of
MLCK and three out of the four of these cases also demonstrate
very early recurrence (2 months, 5 months, 10 months, & the
longest with 21 months recurrence, respectively). Perhaps these
four cases would benefit from MLCK inhibitor therapy if patient
stratification were based on high expression of the drug target in
tumor versus non-tumor. Case 10 showed the lowest levels of
MLCK in tumor compared non-tumor correlating with this case
showing the longest time before recurrence of 31 months. MLCK
also plays a role in p38 MAPK signaling a pathway demonstrating
increased activity in several of the tumors in this study, as discussed
later.
Observing increased Myosin expression in tumor tissue is also of
particular interest as MYH9 (median log2 T/NT = 0.29 and p-
value = 5.93E-03), MYH10 (median log2 T/NT = 0.23 and p-
value = 2.18E-02), & MYH14 (median log2 T/NT = 0.35 and p-
value = 2.03E-02) are all cellular myosins that are critical to
cytokinesis, cell shape, and specialized functions such as secretion
and capping. During cell spreading these three, play an important
role in cytoskeleton reorganization, focal contacts formation (in the
central part but not the margins of spreading cells), and MYH10
induces lamellipodial extension while this function is mechanically
antagonized by MYH9, which is believed to cause lamellipodial
retraction. MYH11 (median log2 T/NT = 0.34 and p-va-
lue = 2.75E-02) is a muscle cell myosin required for muscle
contraction.
In Figure 5 & 6, we select significantly modulated proteins
quantifiable in all 12 cases and associated to the GO terms
‘proliferation’ and ‘DNA damage or DNA repair’, respectively.
Again we see HIPK1 and Mucin-1 selected as proteins of interest
however significant elevated tumor expression of several other
proteins listed here such as STAT3, HDAC1&2, and Hepatoma
derived growth factor also evoke interest especially as they are
potentially effective therapeutic targets to anti-neoplastic agents.
Sum scaling was used to normalise for any adverse effects on
quantification from potential experimental or systematic bias. In
Figure 7 we also display the relative abundance of blood proteins
(Serum albumin and Hemoglobin A&B), the mesenchymal cell
marker (Vimentin), and some cellularity markers (Glyceraldehyde
3-phosphate dehydrogenase & Prelamin A/C). We observe slightly
more GAPDH and Prelamin A/C in the tumor tissue of most
cases. Elevated GAPDH may be due to slightly higher cellularity
or elevated glycolysis in tumor, yet elevated Prelamin A/C is more
suggestive of elevated nuclear envelope and therefore cellularity.
Six out of twelve of the cases display slightly elevated Vimentin
while five out of twelve display slightly reduced levels of Vimentin.
Vimentin was almost two fold higher in the tumor of case 14
suggesting high mesenchymal cell content in this tumor, perhaps
relevant to case 14 early recurrence after only two months. A
possible concern is the very different relative abundance of
Haemoglobin and Serum albumin from case to case. These blood
proteins are clearly very high in the non-tumor tissue of case 4 and
case 13. Following protein extraction from tissue we performed
protein assay to ensure equal protein amounts in each sample,
however it seems much of the protein content from non-tumor
tissue of case 4 and case 13 is from blood. The high content of
blood proteins in the non-tumor tissue of case 4 and 13 may
slightly skew the relative abundance ratios of other proteins
perhaps explaining the particularly high levels of Myosins, Myosin
light chain kinase, and Filamins in tumor tissue from case 4 and
13. For future investigations we will take steps to remove any
residual blood.
Significantly regulated phosphopeptides
P-values and log2 T/NT ratios for phosphopeptides were
plotted on Volcano plots for IMAC, TiO2, and Non-enriched
arms of the workflow, to detect significant (median log2 T/NT$
0.75 or #20.75 and p#0.05) regulations over all cases, as shown
in Figure 3B–3D. Of the 5409 quantifiable phosphopeptides (File
S4), 635 showed significant regulation (Figure 3B–3D) and these
were from 408 unique proteins. The 408 protein accession
numbers were uploaded to the DAVID bio-informatics resource
which matched 14 of these proteins to the Tight Junction signaling
pathway; the KEGG signaling pathway seen to be most
significantly modulated in tumor relative to non-tumor
(p = 2.50E-05). In addition to determining which phosphopeptides
demonstrated significant differences in abundance between tumor
and non-tumor tissue when averaged across all cases, we also
wanted to determine which phosphopeptides were highly modu-
lated on a case by case basis. Accession numbers of proteins which
yielded phosphopeptides demonstrating log2 T/NT ratios of $1,
or #21 (More than 2 fold up-/down- regulated), were selected
separately from each case. Accession numbers were then uploaded
to the DAVID Bioinformatic resource which identified KEGG
signaling pathways which matched with greatest significance for
each case based on p-values and Benjamini scores (Table S7, in
Tables S1). KEGG pathways in Table S7 in Tables S1 with
Benjamini scores #0.05 were highlighted in Yellow. Based on p-
Figure 3. Number of significantly modulated proteins and phosphopeptides. Volcano plots showing 2log10 P-values in relation to log2 T/
NT ratios for; A: relative protein abundance (determined from median non-phosphopeptide log2 T/NT ratios), B: phosphopeptides measured in the
IMAC, C: TiO2, D: and Non-enriched arm of the SysQuant workflow. Red circles point out significantly modulated proteins (log2 T/NT ratios $0.3 or
#20.3 and p-values #0.05) and phosphopeptides (log2 T/NT ratios $0.75 or #20.75 and p-values #0.05). E: is a Venn diagram illustrating the
distribution of the 635 phosphopeptides across the three arms of the workflow that were significantly modulated.
doi:10.1371/journal.pone.0090948.g003
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Table 2. The top 12 most significantly up-regulated proteins in tumor compared to non-tumor background tissue, on average
over all 12 cases.
Uniprot-ID Protein p-values log2 T/NT Function Role in cancer References
P14618 Pyruvate kinase
isozymes M1/M2
4.2E-05 0.383 Glycolytic enzyme that catalyzes
the transfer of a phosphoryl
group from phosphoenolpyruvate
(PEP) to ADP, generating ATP
In addition to aerobic
glycolysis, regulates gene
transcription. Isoform M2
phosphorylates histone H3
at T11, which is related to
expression of cyclin D1 and
c-Myc, tumor cell proliferation,
cell-cycle progression, and
brain tumorigenesis.
Yang W, et al. Cell 2012.
Christofk HR, et al.
Nature 2008.
Q86Z02 Homeodomain-
interacting protein
kinase 1
1.6E-04 1.002 Belongs to the Ser/Thr family of
protein kinases and HIPK subfamily.
Phosphorylates p53, DAXX, and
MYB. Prevents MAP3K5-JNK
activation in the absence of TNF.
Known to be upregulated in
many tumor cell lines.
Involved in tumorigenesis
and tumor growth by its
oncogenic and
anti-apoptotic function.
Kondo S, et al. Proc Natl
Acad Sci USA 2003. Lee
D, et al. EMPO Rep 2012.
Q14847 LIM and SH3
domain protein 1
2.0E-04 0.496 Plays an important role in the
regulation of dynamic actin-based,
cytoskeletal activities
Involved in proliferation,
invasion and migration
of cancer cells.
Zhao L, et al. Gut 2010.
Grunewald TG, et al. Br J
Cancer 2007.
P37802 Transgelin-2 2.3E-04 0.519 Contains a conserved actin-binding
domain also known as the
calponin homolog (CH) domain,
suggesting a role in cytoskeletal
organization.
Overexpressed in various
cancers. Higher expression
levels were associated with
metastasis, advanced clinical
stage, and poor survival.
But its biological function
remains unknown.
Zhang Y, et al. Cancer Sci
2010.
Q92538 Golgi-specific brefeldin
A-resistance guanine
nucleotide exchange
factor 1
2.8E-04 1.397 Involved in mitosis. Phosphorylated
by CDK1. Promotes the activation
of ADP-ribosylation factor 5 (ARF5)
through replacement of GDP
with GTP.
Unknown. Morohashi Y, et al.
Biochem J 2010.
P21291 Cysteine and
glycine-rich
protein a1
4.0E-04 0.628 A cytoskeletal lin-11 isl-1 mec-3
(LIM)-domain protein. Involved in
smooth muscle differentiation.
Down-regulated in
hepatocellular carcinoma
and colorectal cancer. But,
its function is unknow.
Miyasaka KY, et al. Proc
Natl Acad Sci U S A.
2007. Hirasawa Y, et al.
Oncology 2006.
Q8WX93 Palladin 7.0E-04 0.588 Cytoskeletal protein that is
required for organization of
normal actin cytoskeleton. Roles
in establishing cell morphology,
motility, cell adhesion and cell-
extracellular matrix interactions.
Overexpressed in breast
cancer. Involved in cell
migration. Plays a key role in
the formation of podosomes,
actin-rich structures that
function in adhesion and
matrix degradation.
Goicoechea SM, et al.
Oncogene 2009.
Q14195-2 Isoform LCRMP-4 of
Dihydropyrimidinase-
related protein 3
7.0E-04 0.555 Necessary for signaling by class 3
semaphorins and subsequent
remodeling of the cytoskeleton.
Plays a role in axon guidance
and cell migration
Unknown. Weitzdoerfer R, et al. J
Neural Transm Suppl.
2001.
Q9NR12 PDZ and LIM domain
protein 7
7.4E-04 0.778 PDZ domain binds actin-binding
proteins such as b-tropomyosin,
while LIM domains interact with
proteins involved in mitogenic or
insulin signaling such as protein
kinases. Involved in bone
morphogenesis.
Promotes cell survival and
chemoresistance by
suppressing p53-mediated
apoptosis. Elicited p53
degradation by inhibiting
MDM2 self-ubiquitination
and increasing its ubiquitin
ligase activity toward p53
in cells.
Jung CR, et al. J Clin
Invest 2010.
P26038 Moesin 7.6E-04 0.334 A membrane-cytoskeleton linking
protein, belongs to the ERM
(ezrin, radixin and moesin) family.
Participates in various signaling
pathways and play a crucial role
in cell morphology, adhesion
and motility.
Involved in actin filament
remodelling and epithelial
mesenchymal transition.
Haynes J, et al. Mol Biol
Cell. 2011.
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values tight junction signaling pathway was determined to be
modulated between tumor compared to non-tumor in all cases
(12/12 cases), followed by adherens junction signaling (10/12
cases) and focal adhesion signaling (10/12). Figure 8 shows the
tight junction, adherens junction and focal adhesion KEGG
signaling pathways and the rectangles marked with red stars
indicate those proteins we identified as phosphorylated across all
12 cases. We also highlight the known anti-cancer drug targets in
these pathways as indicated in the figure legend. In Figure 9, we
display the log2 T/NT ratios of all significantly modulated
phosphopeptides from focal adhesion proteins, tight junction
proteins and adherens junction proteins that were quantifiable in
all twelve cases. We discuss some of these phosphorylation events
and their potential roles in pancreatic cancer in more detail
however it is beyond the scope of this study to discuss all. Our aim
is to make all the data available to the reader, in the form of tables
and supplemental files, but also select particular phosphorylation
events we believe to be of greatest interest and discuss them here in
more detail.
Phosphorylation of proteins associated with cell-cell or
cell-extracellular matrix (ECM) adhesions
On Figure 9 we show significantly elevated levels in tumor
compared to non-tumor of the phosphopeptide containing the
AFAP phosphorylation site S668 (median log2 T/NT = 1.50 and
p-value = 5.94E-03 for Non-enrich, median log2 T/NT = 1.02 and
p-value = 1.15E-02 for TiO2, median log2 T/NT = 1.03 and p-
Table 2. Cont.
Uniprot-ID Protein p-values log2 T/NT Function Role in cancer References
P15941 Mucin-1 8.6E-04 0.873 A transmembrane glycoprotein.
The alpha subunit has cell
adhesive properties. The beta
subunit contains
a C-terminal domain which is
involved in cell signaling, through
phosphorylation and
protein-protein interactions.
An anti-adhesion molecule
that inhibits cell–cell
adhesion. Promoting motility
and invasive properties by
reducing interactions
between integrins and the
extracellular matrix. Involved
in activation of Wnt and
MAP signal pathways, and
repression of the p53 gene.
Yonezawa, et al. Pathol
Int 2011. Wei X, et al.
Cancer Res 2007. Ren J,
et al. J Biol Chem 2002.
Q05682 Caldesmon 9.4E-04 0.597 A cytoskeletal protein. Stabilizes
actin filaments and involves in
myosin-actin interaction. Plays an
essential role during cellular mitosis
and receptor capping.
Inhibitory effects on cell
motility and migration. But
phosphorylation at particular
sites (i.e., S12) reduces the
anti-migratory effect.
Schwappacher R, et al. J
Cell Sci 2013. Mayanagi
T, et al. J Biol Chem 2008.
Log2 T/NT ratios of the non-phosphorylated peptides from each protein were used as surrogates to calculate the relative abundance of the respective proteins. Log2 T/
NT ratios of the non-phosphorylated peptides were averaged over three arms of the workflow (IMAC, TiO2, Non-enrich).
doi:10.1371/journal.pone.0090948.t002
Figure 4. Significantly modulated lamellipodium and focal adhesion proteins. All proteins in this figure were shown to be associated with
the GO terms ‘lamellipodium’ & ‘focal adhesion’ and also shown to be significantly (p#0.05) up- or down- regulated in tumor compared to non-tumor
tissue and quantifiable in each case (e.g. all proteins containing NA for any case were excluded from the table). Log2 T/NT ratios of the non-
phosphorylated peptides from each protein were used as surrogates to calculate the relative abundance of the respective proteins. Log2 T/NT ratios
of the non-phosphorylated peptides were averaged over three arms of the workflow (IMAC, TiO2, Non-enrich).
doi:10.1371/journal.pone.0090948.g004
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value = 4.16E-03 for IMAC). File S4 & S5 also show elevated
levels of peptides containing the AFAP phosphorylation sites S664,
S665, and S668, but no non-phosphorylated peptides were
quantified therefore relative expression of AFAP could not be
quantified. Actin filament-associated protein 1 (AFAP) is an actin
cross-linking protein and has been shown to be significantly
increased in prostate carcinomas relative to normal prostatic
epithelium as well as benign prostatic hyperplasia [42]. Down-
regulation of AFAP has previously been shown to inhibit cell
proliferation and tumorigenicity in pancreatic cancer cell lines and
mouse models. Furthermore, down-modulation of AFAP can
result in decreased cell-matrix adhesion and cell migration,
defective focal adhesions, and reduced integrin beta-1 expression.
Increased expression of AFAP is associated with progressive stages
of prostate cancer and is critical for tumorigenic growth, in part by
regulating focal adhesions in a PKC-dependent mechanism.
Considering the important role AFAP plays in cancer and the
significantly elevated levels of phosphorylated AFAP detected in
pancreatic tumor tissue in this study, we believe AFAP and its
phosphorylation is most likely an important player in pancreatic
cancer particularly cell migration. It is not known which kinase
causes phosphorylation at these particular sites however it is
known that AFAP is a substrate of Src and PKC.
Catenin delta-1 was originally identified as a Src substrate, and
here we observe significantly decreased tumor levels of the
phosphopeptides containing the catenin delta-1 phosphorylation
sites S349, S352, and S857 (Figure 9). As discussed earlier,
quantification of non-phosphorylated catenin delta-1 peptides
confirmed its expression was significantly decreased in tumor
compared to non-tumor tissue, however the reduction in
phosphorylation was more pronounced than the reduction in
expression (File S4 & S5). We also quantified phosphopeptides
containing the catenin delta-1 phosphorylation sites; S47, S252,
S268, S269, S346, S861, and S864, however these were not
significantly modulated (File S4). Decreased expression and
phosphorylation of catenin delta-1 may play a role in epithelial
to mesenchymal transition in pancreatic cancer.
Junctional adhesion molecule A (JAM-A) phosphorylation site
S284 was decreased in tumor tissue compared to non-tumor tissue
of all cases (median log2 T/NT =21.01 & p-value = 6.59E-05 for
IMAC). Phosphorylation of JAM-A at S284 is known to be a
critical step in the formation and maturation of tight junctions
[43]. Here we observe a significant decrease of JAM-A S284
phosphorylation in tumor tissue suggesting there is less tight
junction formation between tumor cells an event that could favour
epithelial to mesenchymal transition (EMT) of the cells and
consequently metastatic spread. We did not quantify any non-
phosphorylated JAM-A peptides however additional JAM-A
phosphopeptides were quantified as shown on File S4 & S5.
Rho guanine nucleotide exchange factor 2 (GEF-H1) is a
microtubule-associated guanine nucleotide exchange factor for
Rho GTPases [44]. Here, in Figure 9, we show significant increase
of the phosphopeptides containing GEF-H1 phosphorylation site
S174 in tumor compared to non-tumor. No non-phosphorylated
peptides from GEF-H1 were quantified so we were not able to
quantify relative protein abundance (File S5), however we did
quantify additional GEF-H1 phosphopeptides containing phos-
phorylation sites S152, S163, S177, S643, S645, and S932. The
doubly phosphorylated peptide containing sites S174 and S177
were also significantly increased but only quantifiable in cases 1–
10, not cases 11–14 (File S4). All GEF-H1 phosphopeptides except
that containing phosphorylation site S643 were elevated on
average in tumor compared to non-tumor. Guanine nucleotide
exchange factors (GEFs) activate monomeric GTPases by stimu-
lating the release of guanosine diphosphate (GDP) to allow binding
of guanosine triphosphate (GTP) [44]. The aberrant activity of
Ras homologous (Rho) family small GTPases (20 human
members) has been implicated in cancer and other human
diseases [44]. However, in contrast to the direct mutational
activation of Ras found in cancer and developmental disorders,
Rho GTPases are activated most commonly in disease by indirect
mechanisms. One prevalent mechanism involves aberrant Rho
activation via the deregulated expression and/or activity of Rho
family guanine nucleotide exchange factors (RhoGEFs). Rho
GTPases specifically regulate actin organization, cell motility
(through formation of lamellipodia and filipodia), polarity, growth,
survival and gene transcription [44]. Rho guanine nucleotide
exchange factors (RhoGEFs), such as GEF-H1, accelerate the
intrinsic exchange activity of Rho GTPases to stimulate formation
of Rho-GTP [44]. File S4 shows some additional GEFs with
significantly increased phosphorylation in tumor compared to
non-tumor, including; Rho guanine nucleotide exchange factor 11
at S251 and Rho guanine nucleotide exchange factor 17 at S420 &
S735. Inversely we observed significantly decreased phosphoryla-
tion of Rho guanine nucleotide exchange factor 12 at T703 &
S1327 & Rho guanine nucleotide exchange factor 17 at S764.
Here we also observe significant decrease in the phosphopeptide
containing Rho GTPase-activating protein 31 phosphorylation site
Figure 5. Significantly modulated proliferation proteins. All proteins in this figure were associated with the GO term ‘proliferation’ and also
shown to be significantly (p#0.05) up- or down- regulated in tumor compared to non-tumor tissue and quantifiable in each case (e.g. all proteins
containing NA for any case were excluded from the table). Log2 T/NT ratios of the non-phosphorylated peptides from each protein were used as
surrogates to calculate the relative abundance of the respective proteins. Log2 T/NT ratios of the non-phosphorylated peptides were averaged over
three arms of the workflow (IMAC, TiO2, Non-enrich).
doi:10.1371/journal.pone.0090948.g005
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S1432. Modulation of phosphopeptides from several other Rho
signal transduction proteins can be observed in File S4 by filtering
for the GO term ‘Rho protein signal transduction’ in the column
entitled ‘GeneOntologyGO’.
Integrin phosphopeptides were also observed to be significantly
modulated however some of these phosphopeptides were not
measureable in all cases (File S4 & S7). The doubly phosphory-
lated peptide containing the Integrin beta-4 phosphorylation sites
S1483 and S1486, was elevated more than two fold in the tumor
tissue compared to non-tumor tissue of case 1. This phosphopep-
tide was found to be significantly elevated in tumor tissue
compared to non-tumor across all measured cases. Integrin beta-
4 phosphorylation has been associated with the disassembly of cell
anchoring junctions, such as hemidesmosomes at the trailing edge
of migrating cells [45,46]. Such phosphorylation events have been
shown to be induced by Fyn (primarily at Tyrosine residues), PKC
(primarily at Serine residues), and other kinases [45].
Catenin alpha-1. The singly phosphorylated peptide con-
taining Catenin alpha-1 phosphorylation site S655 was elevated
more than two fold in tumor tissue compared to non-tumor, in
case 1 and in fact significantly elevated in tumor tissue on average
across all cases (Figure 9). Phosphorylation at S641, S655, and
S658, was elevated in tumor tissue of all but three cases (File S4),
two of those three being stage IIA. Interestingly phosphorylation of
catenin alpha-1 at S641 has been shown to lead to dissociation
between catenin alpha-1 and catenin beta-1 (beta catenin), leading
to increased transcriptional activation of beta-catenin and tumor
cell invasion [47].
Phosphorylation of protein kinases
In File S4, we filtered all proteins containing ‘kinase’ in their
name and imported these to Figure 10 & File S7. The
phosphopeptides in Figure 10 are quantifiable in all twelve cases
and significantly modulated in tumor compared to non-tumor. Of
particular interest was the observation that the phosphopeptides
from Serine/Threonine-protein kinase MRCK alpha containing
phosphorylation site S1629 were significantly elevated in tumor
compared to non-tumor. In fact, only in case 12 did we not see an
increase of this phosphopeptide in tumor tissue. In addition, File
S7 (Sheet; All Kinase phos) shows that phosphopeptides containing
MRCK alpha phosphorylation sites 1629, 1635, 1651, and 1654
were elevated in tumor relative to non-tumor, for most cases.
MRCK alpha is an important downstream effector of the Rho
GTPase, CDC42, and plays a critical role in the regulation of
cytoskeleton reorganization, formation of cell protrusion, and
promotes cell migration. The specific role of the phosphorylation
event S1629 is not yet known. We were only able to determine
relative expression of MRCK in Cases 7–10 (File S5). We can also
see on Figure 10, that tumor tissue showed elevated phosphory-
lation of; AP2-associated protein kinase 1, Dual specificity
mitogen-activated protein kinase kinase 2 (MEK 2), HIPK1,
Serine/threonine-protein kinase PAK 4 (Isoform 2) and Mitogen-
activated protein kinase kinase kinase 7 (TAK1). MEK2 is known
to be downstream of RAS/RAF and upstream of ERK1/2,
however there is no known function for the significantly up-
regulated in tumor phosphorylation site T394. PAK4 is a serine/
threonine protein kinase that plays a role in a variety of different
signaling pathways including cytoskeleton regulation, cell migra-
Figure 6. Significantly modulated DNA damage and repair proteins. All proteins in this figure were associated with the GO terms ‘DNA
damage’ & ‘DNA repair’, and also shown to be significantly (p#0.05) up- or down- regulated in tumor compared to non-tumor tissue and quantifiable
in each case (e.g. all proteins containing NA for any case were excluded from the table). Log2 T/NT ratios of the non-phosphorylated peptides from
each protein were used as surrogates to calculate the relative abundance of the respective proteins. Log2 T/NT ratios of the non-phosphorylated
peptides were averaged over three arms of the workflow (IMAC, TiO2, Non-enrich).
doi:10.1371/journal.pone.0090948.g006
Figure 7. Mesenchymal (Vimentin), general cellularity and blood protein markers. Log2 T/NT ratios of the non-phosphorylated peptides
from each protein were used as surrogates to calculate the relative abundance of the respective proteins. Log2 T/NT ratios of the non-phosphorylated
peptides were averaged over three arms of the workflow (IMAC, TiO2, Non-enrich).
doi:10.1371/journal.pone.0090948.g007
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tion, growth, proliferation and cell survival. Similarly to MRCK
alpha, PAK4 is activated by GTPases CDC42 and RAC1 which
results in a conformational change and a subsequent autophos-
phorylation on several serine and/or threonine residues, then
activates the downstream target RHOA that plays a role in the
regulation of assembly of focal adhesions and actin stress fibers.
Significantly elevated phosphorylation of TAK1 on S389 &
S439 in tumor tissue relative to non-tumor is also highly
interesting, as TAK1 is a serine/threonine kinase which acts as
an essential component of the MAP kinase signal transduction
pathway. TAK1 mediates signal transduction of TRAF6, various
cytokines including interleukin-1 (IL-1), transforming growth
factor-beta (TGFB), TGFB-related factors like BMP2 and
Figure 8. Signaling pathways highly modulated in pancreatic cancer. This schema summarizes all proteins identified as phosphorylated
from the following KEGG signaling pathways; Tight Junction, Adherens Junction and Focal Adhesion. Red stars indicate those proteins identified as
phosphorylated in any of 12 cases. Proteins highlighted by coloured circles are known drug targets.
doi:10.1371/journal.pone.0090948.g008
Phosphorylome in Pancreatic Cancer
PLOS ONE | www.plosone.org 13 March 2014 | Volume 9 | Issue 3 | e90948
BMP4, toll-like receptors (TLR), tumor necrosis factor receptor
CD40 and B-cell receptor (BCR). It also induces activation of
MKK/JNK signal transduction cascade and the p38 MAPK
signal transduction cascade through the phosphorylation and
activation of several MAP kinase kinases. Considering the role
TAK1 plays in activating signaling cascades, we believe phos-
phorylation of TAK1 at S389 & S439 may be of importance in
pancreatic cancer.
Phosphorylation of proteins associated with GO terms
‘DNA damage’ & ‘DNA repair’
Ten out of the twelve patients experienced tumor recurrence at
various time points after surgery and gemcitabine chemotherapy.
In fact 95% of patients with pancreatic cancer are expected to
show recurrence within 5 years of surgery and chemotherapy,
therefore even though cases 6 and 8 are yet to experience
recurrence we would expect this to occur eventually. Gemcitabine
is a nucleoside analogue used as chemotherapy. As with
fluorouracil and other analogues of pyrimidines, the drug replaces
one of the building blocks of nucleic acids, in this case cytidine,
during DNA replication. The process arrests tumor growth, as new
nucleosides cannot be attached to the ‘‘faulty’’ nucleoside,
resulting in apoptosis (cellular ‘‘suicide’’). Clearly however, the
inevitable problem of recurrence means the DNA damage induced
by gemcitabine is not always catastrophic enough to induce
apoptosis in all pancreatic cancer cells. Usually following DNA
damage the cells sense this due to DNA damage sensing proteins
which activate DNA repair mechanism and if the damage is too
great then they trigger apoptosis. Sometimes however the DNA
repair mechanisms can rescue the cancer cells from apoptosis
therefore leading to chemotherapy resistance and ultimately
recurrence and death. This resistance can be seen in glioblastoma
patients receiving DNA damaging chemotherapies who overex-
press the DNA repair enzyme (O6-methylguanine-DNA-methyl-
transferase (MGMT)); whereas patients with hyper-methylation of
the MGMT gene respond much better to these alkylating
chemotherapies. Epigenetic silencing of the MGMT gene by
methylation of the CpG islands of the promoter region has been
shown to correlate with loss of gene transcription and protein
expression. Loss of expression of the MGMT protein results in
decreased DNA repair and retention of alkyl groups, thereby
allowing alkylating agents such as carmustine (BCNU), lomustine
(CCNU), and temozolomide to have greater efficacy in patients
whose tumors exhibit hypermethylation of the MGMT promoter
and reducing the MGMT protein concentration. [48]. This
relationship between decreased expression of a DNA repair
protein (MGMT) and better response to alkylating chemotherapies
lead us to investigate the expression and phosphorylation status of
DNA damage sensing proteins and DNA repair proteins in our
dataset. In File S4, we filtered all proteins associated with the GO
Figure 9. Significantly modulated phosphopeptides from key signaling proteins. All phosphopeptides here were significantly modulated
in tumor compared to non-tumor tissue in at least one arm of the SysQuant workflow, quantifiable in all 12 cases, and from proteins shown to be
associated with the Focal Adhesion (FA), Adherens Junction (AJ), and Tight Junction (TJ) KEGG signaling pathways. Here we display the KEGG
pathway associated to the protein, the protein name, the global position of the phosphorylation site on the full length protein, the sequence of the
quantified phosphopeptides where lower case s/t/y signifies the phosphorylated residues, the median log2 T/NT ratio over all three arms (non-
enriched, TiO2 & IMAC) in each case, the t-test p-values calculated from all 12 cases for each arm of the workflow, and the median log2 T/NT ratio from
all cases in either the non-enriched arm or TiO2 arm, or IMAC arm of the workflow.
doi:10.1371/journal.pone.0090948.g009
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terms ‘DNA damage’ and/or ‘DNA repair’, then exported all of
those significantly modulated phosphopeptides to Figure 11.
Interestingly we identify two additional kinases (Mitogen-activated
protein kinase 14 & Serine/Threonine-protein kinase SMG1) that
were not shown in Figure 10, as Figure 10 only contained
phosphopeptides that were quantifiable in all 12 cases. Mitogen-
activated protein kinase 14 (MAP kinase p38 alpha) & Serine/
Threonine-protein kinase SMG1 (SMG-1) both contained signif-
icantly elevated phosphopeptides in tumor compared to non-
tumor however these were only quantified in cases 7–10 and cases
7–14, respectively. MAP kinase p38 alpha is activated by cell
stresses such as DNA damage and heat shock, as well as pro-
inflammatory stimuli such as interleukin-1. Activation occurs
through dual phosphorylation of Thr-180 and Tyr-182 by either
of two dual specificity kinases, MEK3 or MEK6, and potentially
also MEK4. MAP kinase p38 alpha phosphorylated on both Thr-
180 and Tyr-182 is 10–20-fold more active than MAP kinase p38
alpha phosphorylated only on Thr-180, whereas MAP kinase p38
alpha phosphorylated on Tyr-182 alone is inactive. Figure 11
demonstrates that MAP kinase p38 alpha must be greater than two
fold more active in tumor tissue of cases 8, 9 & 10, compared to
their respective non-tumor tissue.
Phosphorylation events that indicate activation status of
drug targets
To ascertain relative activation status of known drug targets in
tumor compared to non-tumor tissue in each case, we used relative
abundance of phosphopeptides containing phosphorylation sites
known to either induce enzyme activation or inhibition of such
drug targets. Figure 12 short lists all such phosphopeptides.
Fyn. The relative abundance of the peptide containing
phospho-S21 of the Tyrosine-protein kinase Fyn is elevated more
than two fold in tumor tissue compared to non-tumor tissue of case
1 (Figure 12). Phosphorylation of Fyn at serine 21 is reported to
activate Fyn kinase [49]. This suggests therefore, that Fyn is more
active in the tumor tissue compared to non-tumor tissue of case 1.
Interestingly, phospho-serine 21 of Fyn is detected in all 12 cases,
but it is only in cases 1, 8, 10, 13, and 14, that we observe elevated
levels in tumor compared to non-tumor. Inversely, the tumor
tissue of case 7 shows over a two-fold decrease of this
phosphopeptide compared to non-tumor tissue. Fyn is a target
of the approved kinase inhibitor Dasatinib therefore measurement
of the peptide containing phospho-S21 using our workflow may be
an attractive predictive marker for this drug.
MAPK1 (ERK2). The relative abundance of the peptide
containing phospho-T185 and phospho-Y187 of MAPK1 is
elevated more than two fold in tumor tissue compared to non-
tumor tissue of cases 5, 8, and 10 (Figure 12 and Table S8, in
Tables S1). Phosphorylation of MAPK1 at T185 and/or Y187 is
reported to activate MAPK1 [50]. This suggests therefore, that
MAPK1 is more active in the tumor tissue compared to non-
tumor tissue of cases 5, 8, and 10. Inversely, the tumor tissue of
cases 4 and 11 shows more than two fold reduction of this
phospho-T185 and phospho-Y187 containing phosphopeptide,
compared to non-tumor tissue. MAPK1 is an anti-cancer drug
target (AEZS-131 and SCH772984) and is also down-stream of
many other anti-cancer drug targets (Anti-HER TKIs, Anti-MEK
KIs), therefore measurement of the peptide containing phospho-
T185 and phospho-Y187 using our workflow may be a predictive
marker for these targeted anti-cancer therapies. We have also
measured the singly phosphorylated peptides containing phospho-
T185 or phospho-Y187, as well as the MAPK2 (ERK1) doubly
and singly phosphorylated peptides containing phospho-T202 and
phospho-Y204. SysQuant enables us to determine whether
MAPK2 is phosphorylated on T202 and/or Y204 and/or
MAPK1 is phosphorylated on T185, and/or Y187, yielding
critical signaling pathway activation status information, unattain-
able by western blotting and other antibody based assays.
AKT1. The relative abundance of the singly phosphorylated
peptides containing phospho-S124 and the doubly phosphorylated
peptide containing phospho-S124 and phospho-S129 of AKT1 are
elevated more than two fold in tumor tissue compared to non-
tumor tissue of cases 4, 7, 10, and 13 (Figure 12 and Table S8, in
Tables S1). Phosphorylation of AKT1 at S124 and/or S129 is
reported to activate AKT1 [51,52]. This suggests that AKT1 is
more active in the tumor tissue compared to non-tumor tissue of
cases 4, 7, 10, and 13, therefore anti-AKT kinase inhibitors may
be effective in these patients. Interestingly Case 10 also demon-
strated elevated MAPK1 activity suggesting this patient may be a
candidate for dual AKT1 & MAPK1 inhibitor treatment, as such
combination strategies have proven efficacy in pancreatic cancer
cell lines and xenograft models [12]. Inversely, the relative lower
abundance of phosphopeptides containing these activator phos-
phorylation sites suggests AKT1 is less active in the tumor tissue
compared to non-tumor tissue of cases 1, 6, 8, 9, 11, and 14.
RAF1 & BRAF. Both are targets of Sorafenib the approved
targeted therapy for advanced renal cell carcinoma and advanced
hepatocellular carcinoma (HCC). The phosphopeptides contain-
ing the activator phosphorylation site S621 on RAF1 was elevated
more than two fold in tumor compared to non-tumor of cases 10
and 13, suggesting elevated RAF1 activity in these cases. In tumor
of case 14 there appears to be subtle increase in the activator
phosphorylation sites S621 on RAF1 and S729 on BRAF, yet
strong decrease in the inhibitor phosphorylation site S259 on
RAF1, suggesting RAF1 and BRAF are more active in the tumor
tissue of case 14. In future studies we plan to determine whether
RAF1 and BRAF phosphorylation status serve as predictive
markers to Sorafenib therapy in patients with advanced HCC. We
also show ARAF phosphorylation on Figure 12, despite ARAF not
being a known drug target of Sorafenib.
GSK3a. The peptide containing the Glycogen synthase
kinase-3 alpha phosphorylation site Y279 increased more than
two fold in the tumor tissue compared to non-tumor tissue of cases
1, 6, 13, and 14 (Table S8, in Tables S1, and File S4).
Phosphorylation of Y279 causes activation of GSK3a which then
induces cell survival, and reduces glycogen production [53].
GSK3a expression was measured in 8 out of 12 cases and shown to
be significantly over expressed on average in tumor.
The relative abundance of phosphopeptides containing activa-
tor or inhibitor phosphorylation sites can help determine the
relative activation status of; GSK3a and b, Histone deacetylase 1
and 2, RAF proto-oncogene serine/threonine-protein kinase,
Serine/threonine-protein kinase A-Raf, Dual specificity mitogen-
activated protein kinase kinase 6, Mitogen-activated protein kinase
14 (p38 MAPK), and over 20 others (File S4).
Several limitations need to be considered in this study. First,
phosphorylation status of tissue might have been modified during
sample collection. For example, although tissue samples were snap
frozen 30 minutes after resection, one cannot exclude the
possibility that ischaemia might have affected the phosphorylation
status, however our quality control steps such as PLS-DA suggests
our data has not been adversely affected by such issues. Second, as
whole pieces of tissue were analysed, we cannot determine which
phosphopeptides derives from cancer or stromal cells. However,
considering that not only cancer cells but also stromal components
are potential drug targets (i.e., inhibitors of angiogenesis), whole
tissue samples may prove more helpful in understanding activated
signaling pathways in cancer and to identify potential drug targets
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than micro-dissected cancer cells. Third, a common theme to
current data dependent mass spectrometry is its ability to define
the composition of complex proteomes/phosphorylomes and the
functions of these complexes however ‘‘undersampling’’ still exists,
that is, only a subset of the peptides will be identified if the
complexity of the peptide sample exceeds the analytical capacity of
the mass spectrometer e.g., when more peptides elute from the
HPLC column per unit time than can be analyzed, or low-
abundance peptides are below the instrument detection limit [54].
The undersampling issue (e.g presence of non-availables (N/A))
may explain why we can identify peptides in some but not all of
the three TMT 8-plex analysed in this study. Future instrumen-
tation and fractionation techniques will lead to complete proteome
analysis eradicating undersampling [9].
In summary, we show examples here demonstrating how our
LC-MS/MS proteomic workflow (SysQuant) can simultaneously
measure the expression and phosphorylation of 1000’s of proteins
in tumor tissue relative to non-tumor tissue, and show how such
measurements can be used to better understand the molecular
events leading to cancer, and therefore the most suitable inhibitory
agents, to treat a patient on a case by case basis. Within the field of
LC-MS/MS based proteomics there are many groups developing
very high quality analytical workflows to measure global protein
expression and phosphorylation, however most studies from these
groups are focused purely on either improving the sample
Figure 10. Significantly modulated phosphopeptides from key kinases. All phosphopeptides here were significantly modulated in tumor
compared to non-tumor tissue in at least one arm of the SysQuant workflow, quantifiable in all 12 cases, and from proteins shown to contain the
word ‘kinase’ in their protein name. Here we display the Uniprot accession number, the protein name, the global position of the phosphorylation site
on the full length protein, the sequence of the quantified phosphopeptides where lower case s/t/y signifies the phosphorylated residues, the median
log2 T/NT ratio over all three arms (non-enriched, TiO2 & IMAC) in each case, the t-test p-values calculated from all 12 cases for each arm of the
workflow, and the median log2 T/NT ratio from all cases in either the non-enriched arm or TiO2 arm, or IMAC arm of the workflow.
doi:10.1371/journal.pone.0090948.g010
Figure 11. Significantly modulated phosphopeptides from DNA damage or repair proteins. All phosphopeptides here were significantly
modulated in tumor compared to non-tumor tissue in at least one arm of the SysQuant workflow, and from proteins associated to the GO terms ‘DNA
damage’ or ‘DNA repair’. Here we display the Uniprot accession number, the protein name, the global position of the phosphorylation site on the full
length protein, the sequence of the quantified phosphopeptides where lower case s/t/y signifies the phosphorylated residues, the median log2 T/NT
ratio over all three arms (non-enriched, TiO2 & IMAC) in each case, the t-test p-values calculated from all 12 cases for each arm of the workflow, and
the median log2 T/NT ratio from all cases in either the non-enriched arm or TiO2 arm, or IMAC arm of the workflow.
doi:10.1371/journal.pone.0090948.g011
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preparation, or improving the LC-MS/MS analysis, or improving
the data analysis software tools (computational mass spectrometry
and/or bioinformatics), but rarely are these advancements and
improvements grouped into a seamless workflow and applied to
unravel the molecular events inducing cancer in a clinical setting.
We believe this study builds on and further improves the
technological advances in the field of LC-MS/MS proteomics
and demonstrates how we can translate these into clinical
oncology applications. This study demonstrates that LC-MS/MS
proteomic workflows have the potential to become clinical tests
and may improve clinical outcome for pancreatic cancer patients,
as well as other cancers. In future we aim to improve SysQuant by
reducing the turnaround time to two weeks (from receiving tissue
specimen to interpreting data), reducing required specimen size
from resected tissue to core needle biopsy, and also reducing
economic cost. These are some examples of essential improve-
ments to the current workflow for future applicability as a routine
clinical test.
Throughout the manuscript we selected proteins and phospho-
peptides significantly modulated then determined whether these
proteins are known to contribute to migration, invasion, prolifer-
ation and/or DNA damage/DNA repair. Of particular interest
was the observation of significantly increased expression of HIPK1
& MLCK, as well as observing significant increase in phosphor-
ylation of the Serine/threonine-protein kinase MRCK alpha; as all
three proteins may serve as effective new therapeutic targets.
Despite these significant increases in tumor on average across all
cases, we feel it is also important to highlight the interpatient
variability in the expression and phosphorylation of these and
other proteins e.g. cases 11 & 8 demonstrate substantially higher
levels of HIPK1 in tumor (log2 T/NT of 3.00 & 2.51, respectively),
while cases 7 & 6 do not show such high expression (log2 T/NT of
0.45 & 0.55, respectively); cases 13 & 4 demonstrate substantially
higher levels of MLCK in tumor (log2 T/NT of 2.05 & 1.84,
respectively), while cases 10 & 12 show reduced expression in
tumor (log2 T/NT of 20.67 & 20.17, respectively); and finally
cases 8 & 14 demonstrate substantially higher levels of phosphor-
ylation of MRCKa in tumor (log2 T/NT.3.00 & .2.00,
respectively), while case 12 shows reduced phosphorylation in
tumor. This interpatient variability again highlights the need for
suitable analytical capabilities, such as SysQuant, to determine the
molecular events likely contributing to cancer from patient to
patient, to then design more appropriate and bespoke treatment
strategies for each case. Due to the volume of data, we have not
been able to investigate the importance of every interesting
molecular event observed here, and therefore invite experts from
the oncology community focussed on specific areas of research to
download our supplemental files (especially Files S4, S5, S6, and
S7) and identify molecular events they feel also contribute to the
cancer phenotype and therefore hopefully develop more effective
therapeutics specific to inhibiting cancer. Our data gives a unique
insight into the expression levels and phosphorylation status of
thousands of proteins in clinical tumor tissue relative to the non-
tumor background tissue. This data can be used to help validate
theories and proposed mechanisms originating from functional
investigations in model systems or the pre-clinical setting.
Supporting Information
Figure S1 A: This MA-plot shows the log ratios vs. the log
intensities over the complete non-normalized data set. B: This
Figure 12. Phosphorylation indicates activity of drug targets. Here are examples of phosphopeptides that contain activator and inhibitor
phosphorylation sites on proteins known to be anti-cancer drug targets. Here we display the inhibitory drug, the protein name, the global position of
the phosphorylation site on the phosphoprotein, and the sequence of the phosphopeptide. The phosphorylated s/t/y residue in each peptide
sequence is in lower case. The log2 T/NT ratios displayed in each case were median values calculated from all three arms of the workflow.
Phosphopeptides in red contain activator phosphorylation sites, while phosphopeptides in blue contain inhibitor phosphorylation sites.
Phosphopeptides in black contain phosphorylation sites with no known function.
doi:10.1371/journal.pone.0090948.g012
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MA-plot shows the same as Figure S1A, but the data was
normalized by sum-scaling and therefore better zero-centred.
(PPTX)
Figure S2 Number of unique phosphopeptides and non-
phosphopeptides identified in each raw file, from each
SCX fraction, in each arm of the workflow (non-enrich,
TiO2, and IMAC), from each TMT 8-plex sample (TMT
8-plex-1 shown in S2A, TMT 8-plex-2 shown in S2B, &
TMT 8-plex-3 shown in S2C). Most of the non-phosphory-
lated peptides eluted in fractions 7 to 11, while the phosphorylated
peptides started to elute earlier but were more evenly distributed
throughout the chromatography run time, except for a clear spike
in the elution of phosphopeptides in fraction 6 from TMT 8-plex-
1,2&3 (IMAC), fraction 6 from TMT 8-plex-2&3 (TiO2), and
fraction 5&6 from TMT 8-plex-1 (TiO2).
(PPTX)
Figure S3 A: Hoteling T-Range plot shows no outlier’s at the T2
plot. B: PC1 and PC2 Score plot of the first two principal
components describing 13.6% (PC1) and 10.6% (PC2) of the total
variance in the data. The circle depicts the T2 hotelling space
based on 95% confidence. C: PLS Loading-plot PC1 and PC2.
(PPTX)
Figure S4 A: PLS Loading plot PC2 and PC3. B: PC2 and PC3
Score plot of the next principal components describing 10.6%
(PC2) and 14.4% (PC3) of the total variance in the data. C: Here
we zoom in on the total protein (non-enriched) cluster in Figure
S4B. D: The same Score plot like Figure S4B, only the enrichment
description in the label was deleted. E: Here we zoom in on the
total protein (non-enriched) cluster in Figure S4D.
(PPTX)
File S1 This is a zip excel file containing a list of all
peptides (phosphorylated and non-phosphorylated)
identified from all eight specimens in the TMT 8-plex-
1 sample. The file displays detailed information including;
Sequest Xcorr, Mascot ions scores, DM [ppm], Percolator q-
values, pRS-probabilities, raw quantification values, and other
important information.
(7Z)
File S2 This is a zip excel file containing a list of all
peptides (phosphorylated and non-phosphorylated)
identified from all eight specimens in the TMT 8-plex-
2 sample. The file displays detailed information including;
Sequest Xcorr, Mascot ions scores, DM [ppm], Percolator q-
values, pRS-probabilities, raw quantification values, and other
important information.
(7Z)
File S3 This is a zip excel file containing a list of all
peptides (phosphorylated and non-phosphorylated)
identified from all eight specimens in the TMT 8-plex-
1 sample. The file displays detailed information including;
Sequest Xcorr, Mascot ions scores, DM [ppm], Percolator q-
values, pRS-probabilities, raw quantification values, and other
important information.
(7Z)
File S4 In this excel file we display all measurable
phosphopeptides (5409) in all cases (12) from all arms of
the workflow (non-enrich, IMAC, TiO2). We display the
Uniprot accession number, full protein name, phosphorylated
residue number on full length protein, identified peptide sequence,
confidence score of phosphorylated residue (pRS probability), t-
test p-values for each arm of the workflow, and log2 T/NT ratios
for each phosphopeptide on average across all cases, and in each
individual case. We also display biological/functional relevant
information if known to each phosphosite (from PhosphoPhosite-
Plus), and to each protein (from GO and DrugBank databases).
(XLSX)
File S5 In this excel file we display all measurable
phosphopeptides but also display the relative protein
abundance. Relative protein abundance was determined by
measuring the relative abundance of all non-phosphorylated
unique to a specific protein (non-shared/non-homologous pep-
tides). Here we also normalise phosphopeptide levels to relative
protein abundance.
(XLSX)
File S6 All proteins listed in this excel file were shown
to be significantly up- or down-regulated in tumor
compared to non-tumor tissue. In the first sheet, proteins
were deemed significantly modulated if they displayed p-values#
0.05. In the second sheet of the file, proteins were deemed
significantly modulated if they displayed log2 T/NT#20.3 or $
0.3 & p-values#0.05. In the third sheet of the file proteins were
deemed significantly modulated if they were measureable in tumor
and non-tumor of all twelve cases (e.g. no non-available) and
displayed log2 T/NT#20.3 or $0.3 & p-values#0.05. The other
sheets in this excel file contained significantly modulated proteins
associated to the GO terms, DNA damage and repair,
proliferation, focal adhesions and lamellipodia, and others.
(XLSX)
File S7 Here, in the first sheet of this excel file, we
display all significantly modulated phosphopeptides
from proteins associated with Tight Junctions, Adherens
Junctions, and Focal Adhesions. In the second sheet we
display Integrin phosphopeptides. In the third sheet we display all
phosphophopeptides from Kinases. In the fifth sheet we filter
significantly modulated phosphopeptides (p#0.05) from kinases
which were measureable in all specimens. In the sixth sheet we
display all phosphopeptides from DNA repair proteins and in the
seventh sheet filter all those phosphopeptides from DNA repair
proteins which were significantly modulated (p#0.05). In the
eighth sheet we display all those phosphopeptides from proteins
associated with the GO term ‘migration’.
(XLSX)
Methods S1 This document contains supplemental
methods.
(DOCX)
Tables S1 This document contains Tables S1–S8. Table
S1, Fourteen cases of pancreatic head ductal adenocarcinoma
were selected from Institute of Liver Studies BioBank. Specimens
from cases 2 and 3 yielded low protein amounts during protein
extraction therefore were omitted from the study. Table S2,
Information on tumor stage and recurrence are shown here.
Yellow cases showed recurrence between 2 & 31 months after
tumor removal. The difference between stage IIA and IIB is only
the presence or absence of lymph node metastasis. Table S3,
Additional non-confidential clinical information about patient and
tumor. Table S4, Protein amounts from each sample per TMT 8-
plex, used for the SysQuant workflow in this study. Table S5,
Peptides from each specimen are labelled with different tandem
mass tags (TMT). All peptides from case 1 tumor, case 10 non-
tumor, and case 11 tumor were labelled with the 126 Da tandem
mass tag (TMT) while peptides from case 1 non-tumor, case 10
tumor and case 11 non-tumor were labelled with the lighter
127 Da tandem mass tag (TMT), and so on as shown below. The
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lighter 127 (127e) and heavier 127 only differ in mass by 6 milli-
Daltons, as do 129e and 129 reporter ions. Table S6, Nine aliquots
of TMT labelled peptides were separated by SCX-HPLC. Table
S7, Accession numbers of proteins which yielded phosphopeptides
demonstrating log2 T/NT ratios of$1, or#21 (More than 2 fold
up/down- regulated), were selected separately from each case.
Accession numbers were then uploaded to the DAVID Bioinfor-
matic resource (separately for each case) which identified KEGG
signaling pathways matched with greatest significance based on p-
values and Benjamini scores. KEGG pathways with Benjamini
scores#0.05 were highlighted in Yellow. Table S8, Case by case –
Here we selected all phosphopeptides displaying log2 T/NT ratios
$1 or #21, that also contain phosphorylation sites that are
known to either induce activation or inhibition of the
phosphorylated enzyme (based on PhosphoSitePlus database).
This was done for each case, on a case by case basis. T/NT is the
average log2 ratio of phosphopeptide in tumor versus background
tissue observed across all three arms of the workflow (IMAC,
TiO2, Non-enrich). We also indicate whether the enzyme is a drug
target based on the Drug Bank database.
(DOCX)
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